Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Regn save search
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
Published: 2024-03-13 (Crawled : 02:00) - globenewswire.com
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: -1.46%
million cancer research
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
Published: 2023-05-02 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -5.0%
H: 1.66%
C: 1.66%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.0%
H: 1.06%
C: -1.03%
asco cancer research
Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Published: 2023-03-29 (Crawled : 12:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.37%
H: 0.6%
C: -1.28%
libtayo lung approved positive cancer cell treatment
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Published: 2023-02-24 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.11%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.77%
H: 1.52%
C: 0.42%
libtayo treatment lung chmp positive cancer
Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer
Published: 2022-12-23 (Crawled : 14:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.05%
H: 0.22%
C: -0.98%
libtayo japan approved cancer
CANCER RESEARCH INSTITUTE VIRTUAL IMMUNOTHERAPY PATIENT SUMMIT IS NOW AVAILABLE FREE, ON-DEMAND
Published: 2022-12-08 (Crawled : 12:20) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.5%
H: 0.16%
C: 0.16%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: -0.39%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.81%
H: 2.76%
C: 0.97%
research immunotherapy cancer
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology
Published: 2022-11-22 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 2.34%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.66%
H: 0.79%
C: 0.72%
libtayo immunotherapy approved cancer
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Published: 2022-11-17 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.26%
H: 1.16%
C: 0.73%
CTMX | $1.635 -2.68% -2.75% 280K
|
Health Technology
|
| O: 23.14%
H: 12.75%
C: 7.38%
treatment research collaboration therapeutics cancer
CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Published: 2022-11-17 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.26%
H: 1.16%
C: 0.73%
CTMX | $1.635 -2.68% -2.75% 280K
|
Health Technology
|
| O: 23.14%
H: 12.75%
C: 7.38%
treatment research collaboration therapeutics cancer
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
Published: 2022-11-08 (Crawled : 22:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.72%
H: 0.69%
C: -0.23%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.13%
H: 2.48%
C: -1.07%
libtayo treatment fda lung approved cancer
Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
Published: 2022-10-14 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 6.95%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.74%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.0%
H: 1.13%
C: -2.19%
libtayo chmp approval positive cancer
CANCER RESEARCH INSTITUTE TO HOST SECOND-ANNUAL SPANISH-LANGUAGE VIRTUAL IMMUNOTHERAPY PATIENT SUMMIT, MODERATED BY ANA PATRICIA GÁMEZ, TO CONNECT THE U.S. HISPANIC CANCER COMMUNITY WITH INFORMATION THAT CAN SAVE LIVES
Published: 2022-09-06 (Crawled : 14:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.93%
H: 10.14%
C: 3.79%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.54%
H: 3.26%
C: 1.28%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.68%
H: 0.65%
C: -1.81%
research immunotherapy save cancer
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Published: 2022-08-03 (Crawled : 11:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 4.36%
H: 3.91%
C: 1.46%
libtayo antibody cancer prostate cancer pd-1 inhibitor
Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer
Published: 2022-06-02 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.55%
H: 0.0%
C: -0.12%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -2.18%
H: 0.0%
C: -3.71%
libtayo collaboration approved cancer sanofi pd-1 inhibitor
Regeneron and Sanofi Provide Regulatory Update on Libtayo® (cemiplimab-rwlc) in Advanced Cervical Cancer
Published: 2022-01-28 (Crawled : 12:30) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.04%
H: 0.92%
C: 0.82%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.07%
H: 2.75%
C: 2.73%
libtayo cancer
FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.15%
H: 0.06%
C: -0.6%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -1.91%
H: 1.73%
C: -0.37%
fda cancer fda acceptance
Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Published: 2021-08-05 (Crawled : 11:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.32%
H: 2.47%
C: 2.35%
lung cancer therapy cancer phase 3 trial
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Published: 2021-07-27 (Crawled : 14:58) - fda.gov
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -0.05%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.64%
H: 0.68%
C: 0.34%
ADCT | $4.78 -3.82% 0.0% 280K
|
Health Technology
|
| O: -0.05%
H: 1.0%
C: -2.76%
YMAB | $15.26 -0.52% -0.52% 160K
|
Health Technology
|
| O: -0.67%
H: 2.09%
C: -0.18%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.54%
H: 0.65%
C: 0.49%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -1.6%
H: 2.25%
C: 2.2%
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -0.47%
H: 1.53%
C: -0.35%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.41%
H: 0.14%
C: -0.84%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: 2.34%
H: 0.37%
C: -1.69%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: -0.21%
H: 4.42%
C: 2.74%
BPMC | $92.31 0.02% 0.02% 560K
|
Health Technology
|
| O: -0.12%
H: 0.58%
C: -0.16%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -1.17%
H: 2.55%
C: 0.59%
cancer approval
Oncology (Cancer) / Hematologic Malignancies Approval Notifications
Published: 2021-07-22 (Crawled : 11:36) - fda.gov
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.0%
H: 1.02%
C: 0.51%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.03%
H: 1.28%
C: 1.22%
ADCT | $4.78 -3.82% 0.0% 280K
|
Health Technology
|
| O: 0.18%
H: 0.31%
C: -2.26%
YMAB | $15.26 -0.52% -0.52% 160K
|
Health Technology
|
| O: -1.57%
H: 3.71%
C: 0.43%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.12%
C: -0.6%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.36%
H: 1.56%
C: 0.9%
KPTI | $1.1 0.92% 0.91% 1.2M
|
Health Technology
|
| O: -0.53%
H: 0.38%
C: -3.01%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.39%
H: 0.11%
C: -0.27%
EPZM | $1.47 -1.34% 0.0%
|
Health Technology
|
| O: -1.49%
H: 2.0%
C: -2.34%
CLVS | $0.0812 -3.94%
|
Health Technology
|
| O: 0.0%
H: 0.58%
C: -3.46%
BPMC | $92.31 0.02% 0.02% 560K
|
Health Technology
|
| O: -0.84%
H: 1.72%
C: 0.61%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 2.21%
H: 0.0%
C: -4.87%
cancer approval
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.